

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



ETHK Labs Inc.

華檢醫療控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1931)

CHANGE IN COMPOSITION OF THE BOARD OF DIRECTORS

ETHK Labs Inc. (the “**Company**”, together with its subsidiaries, the “**Group**”) announces that Ms. Yi Xiao has been appointed as an executive director (a “**Director**”) and chief scientist of the Company with effect from 6 February 2026.

Biography of Ms. Yi is set out below:

Ms. YI Xiao (易笑), aged 32, obtained a Bachelor of Medicine from the University of South China in June 2016, majoring in clinical medicine, and a Doctor of Medicine from Southern Medical University in June 2022, majoring in obstetrics and gynaecology.

Ms. Yi has been a professor at the Translational Medicine Centre of Zhujiang Hospital of Southern Medical University in July 2022, and a part-time young researcher of the Greater Bay Area Institute of Precision Medicine (Guangzhou) in 2023. Ms. Yi is also a chief scientist of the Company with effect from 6 February 2026.

Ms. Li became a member of the Youth Academic Group of the Sixth Committee of the Reproductive Medicine Branch of the Chinese Medical Association in May 2025. She became an early career editorial board member of Interdisciplinary Medicine in October 2024, a member of the Youth Committee of the 3D Bioprinting and Regenerative Medicine Branch of the Guangdong Society of Biomedical Engineering in June 2024, a standing committee member of the First Committee of the Youth Professional Committee of Obstetrics and Gynaecology of the Guangdong Clinical Medical Association in June 2024, the vice chairperson of the Youth Committee of the Fourth Committee of the Reproductive Medicine Branch of the Guangdong Medical Association in July 2023, a standing committee member of the Second Maternal and Child Health Branch of the Guangdong Society for Translational Medicine in June 2023, and a member of the Committee for the Promotion of Basic and Clinical Research of the China Medicine Education Association in April 2023.

Ms. Yi has published multiple papers in domestic and international journals, including papers appearing in international publications such as Science Advances, Advanced Materials Biomaterials, Nano Today Engineered Regeneration, Stem Cell Research & Therapy. Ms. Yi has also led multiple research projects, including the National Key Research and Development Program (Young Scientist), the Guangdong Provincial Natural Science Foundation – Outstanding Young Scholars Program, and the Guangdong Science and Technology Program (Key R&D Program). Related products have obtained IND approval and Class III medical device registration certification.

As project leader or primary advisor, Ms. Yi has received various national-level awards and provincial/ministerial-level awards, including the National Gold Award of the China Postdoctoral Innovation and Entrepreneurship Competition and the National Gold Award of the International “Internet+” Innovation and Entrepreneurship Competition.

In accordance with the Company’s articles of association, Ms. Yi will hold office as a Director until the annual general meeting to be held in 2026 (and be eligible for re-election). It is expected that Ms. Yi will enter into a service agreement with the Company, subject to termination by either party’s three-month notice. Her tenure is also subject to other provisions relating to termination, retirement and re-election in the service agreement and under the Company’s articles of association. It is expected that under the service agreement, Ms. Yi will be entitled to a monthly director’s remuneration of HK\$30,000, and is eligible to receive discretionary bonuses, other benefits and allowances (including the Group’s contribution of applicable provident fund and share scheme). Ms. Yi’s remuneration was recommended by the remuneration committee of the Company and approved by the board of Directors (the “**Board**”) in accordance with the Company’s remuneration policy for Directors, with reference to her roles, duties and responsibilities, her background, as well as the comparable market practice, and are subject to revision in future by the decision of the Board based on the recommendation of the remuneration committee.

Ms. Yi confirmed that, save as disclosed in this announcement (i) she does not have any relationship with any of the Directors, senior management or substantial or controlling shareholders of the Company (as defined under The Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”)) as at the date of this announcement; (ii) she has not held any other directorships in other public companies the securities of which are listed on any securities market in Hong Kong or overseas in the preceding three years; (iii) she does not have any interests in the shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance; and (iv) there is no other information required to be disclosed pursuant to Rule 13.51(2) of the Listing Rules. The Company is not aware of any other matters relation to Ms. Yi’s appointment that need to be brought to the attention of the shareholders of the Company.

By order of the Board
ETHK Labs Inc.
Lin Xianya
Executive Director

Hong Kong, 6 February 2026

As at the date of this announcement (and following the change of composition of the Board mentioned in this announcement becoming effective), the Board comprises three executive directors, namely, Mr. Lin Xianya, Mr. Chan Siu Kei Ken and Ms. Yi Xiao, two non-executive directors, namely, Ms. Yao Haiyun and Mr. Liu Fei and three independent non-executive directors, namely, Dr. Zhong Renqian, Mr. Xu Da and Mr. Zhang Jianlei.

In this announcement, certain Chinese names of institutions, natural persons or other entities have been translated into English and included as unofficial translations for identification purposes only. In the event of any inconsistency, the Chinese names shall prevail.